TNF受体1相关周期性综合征(TRAPS)相关AA淀粉样变性:全国病例系列与系统综述
本文通过法国全国回顾性病例系列(2000–2020年)及截至2021年2月的系统文献综述,共分析41例TRAPS合并AA淀粉样变性患者。结果显示96%的病例AA诊断先于TRAPS诊断,47%需肾脏替代治疗,14%死亡;生物制剂治疗21个方案中10个改善肾功能、7个稳定、4个恶化。结论提示AA常为TRAPS首发表现,应对AA患者筛查TRAPS临床特征,IL-1拮抗剂有助于控制炎症和保护肾功能。
要点
- AA淀粉样变性在多数TRAPS患者中先于TRAPS诊断出现,应主动筛查。
- 47%的TRAPS相关AA患者需肾脏替代治疗,14%死亡。
- 生物制剂治疗中约半数改善肾功能,IL-1拮抗剂可能有助于保护肾功能。
核心结论
- TRAPS多数以AA淀粉样变性为首发表现,应对AA患者筛查TRAPS临床特征。
- IL-1拮抗剂有助于控制炎症并保护肾功能。
研究设计与样本
- 法国单中心2000–2020年回顾性病例系列,纳入组织学确诊AA的TRAPS患者3例。
- 系统文献综述检索PubMed和EMBASE截至2021年2月,按PRISMA指南,补充38例文献病例。
主要发现
- 共分析41例TRAPS合并AA患者,其中3例新发、38例来自文献。
- AA诊断先于TRAPS诊断的比例为96%。
- 17/36(47%)患者需要肾脏替代治疗。
- 中位随访23个月期间,5/36(14%)患者死亡。
- 19例患者共21个生物制剂治疗方案中,10个改善肾功能、7个稳定、4个恶化。
临床怎么用
- 对AA淀粉样变性患者应筛查TRAPS的临床特征。
- TRAPS相关AA患者可考虑IL-1拮抗剂以控制炎症和保护肾功能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: TNF receptor-1-associated periodic syndrome (TRAPS) is a rare autosomal dominant autoinflammatory disorder associated with mutations in the TNF receptor super family 1 A (TNFRSF1A) gene. AA amyloidosis (AA) is the most severe complication of TRAPS. To study the occurrence and prognosis of AA in TRAPS, we conducted a retrospective study of all French cases and a systematic literature review. METHODS: This case series includes TRAPS patients followed by our centre from 2000 to 2020 presenting with histologically confirmed AA. We conducted a systematic literature review on the PubMed and EMBASE databases for articles published up to February 2021 following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines and using the keywords: amyloidoisis, amyloid, TNF receptor-associated periodic syndrome, TNF receptor-associated periodic syndrome, tumor necrosis factor receptor-associated periodic syndrome, TRAPS, TNFRSF1A, familial hibernian fever and hibernian familial fever. RESULTS: A total of 41 TRAPS with AA were studied: three new patients and 38 cases from the literature. AA diagnosis preceded that of TRAPS in 96% of cases, and 17/36 (47%) required renal replacement therapy. Death occurred in 5/36 (14%) with a median follow-up of 23 months. Effect of biologics on AA were available for 21 regimens in 19 patients: 10 improved renal function, seven stabilized and four worsened. Four patients (36% of transplanted patients) relapse AA on kidney graft (only one under etanercept). CONCLUSION: TRAPS is revealed by AA in most cases. Therefore, clinical features of TRAPS should be screened for in AA patients. IL-1 antagonist can help to normalize inflammation and to preserve renal function.
引用
- Delaleu J, Deshayes S, Rodrigues F, et al. Tumour necrosis factor receptor-1 associated periodic syndrome (TRAPS)-related AA amyloidosis: a national case series and systematic review. Rheumatology (Oxford). 2021. PMID: 33715002. doi:10.1093/rheumatology/keab252
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。